2seventy bio, Inc. (NASDAQ:TSVT) Shares Bought by Geode Capital Management LLC

Geode Capital Management LLC lifted its stake in shares of 2seventy bio, Inc. (NASDAQ:TSVT) by 1.1% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,176,244 shares of the company’s stock after buying an additional 13,144 shares during the quarter. Geode Capital Management LLC owned approximately 2.28% of 2seventy bio worth $5,553,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors have also made changes to their positions in the stock. Venator Management LLC lifted its holdings in 2seventy bio by 49.2% during the 2nd quarter. Venator Management LLC now owns 485,000 shares of the company’s stock worth $1,867,000 after buying an additional 160,000 shares during the last quarter. BBR Partners LLC boosted its stake in 2seventy bio by 620.0% in the third quarter. BBR Partners LLC now owns 180,000 shares of the company’s stock valued at $850,000 after acquiring an additional 155,000 shares during the period. GSA Capital Partners LLP bought a new position in shares of 2seventy bio during the third quarter valued at approximately $64,000. FMR LLC raised its position in shares of 2seventy bio by 22.0% during the 3rd quarter. FMR LLC now owns 148,545 shares of the company’s stock worth $701,000 after purchasing an additional 26,738 shares during the period. Finally, XTX Topco Ltd lifted its holdings in shares of 2seventy bio by 61.1% in the 3rd quarter. XTX Topco Ltd now owns 24,416 shares of the company’s stock worth $115,000 after purchasing an additional 9,257 shares during the last quarter. Institutional investors own 93.90% of the company’s stock.

2seventy bio Price Performance

NASDAQ:TSVT opened at $2.91 on Friday. The firm has a market capitalization of $150.12 million, a P/E ratio of -1.56 and a beta of 1.69. The business has a 50 day simple moving average of $3.70 and a 200 day simple moving average of $4.24. 2seventy bio, Inc. has a 12-month low of $2.78 and a 12-month high of $6.40.

2seventy bio Company Profile

2seventy bio, Inc, a cell and gene therapy company, focuses on the research, development, and commercialization of treatments for cancer in the United States. The company's products pipeline includes Abecma, a chimeric antigen receptor T-cell product candidates for the treatment of multiple myeloma.